The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The Direct Medical Cost of Type 2 Diabetes
Abstract
OBJECTIVE—To describe the direct medical costs associated with type 2 diabetes, as well as its treatments, complications, and comorbidities. RESEARCH DESIGN AND METHODS—We studied a random sample of 1,364 subjects with type 2 diabetes who were members of a Michigan health maintenance organization. Demographic characteristics, duration of diabetes, diabetes treatments, glycemic control, complications, and comorbidities were assessed by surveys and medical chart reviews. Annual resource utilization and costs were assessed using health insurance claims. The log-transformed annual direct medical costs were fitted by multiple linear regression to indicator variables for demographics, treatments, glycemic control, complications, and comorbidities. RESULTS—The median annual direct medical costs for subjects with diet-controlled type 2 diabetes, BMI 30 kg/m2, and no microvascular, neuropathic, or cardiovascular complications were $1,700 for white men and $2,100 for white women. A 10-kg/m2 increase in BMI, treatment with oral antidiabetic or antihypertensive agents, diabetic kidney disease, cerebrovascular disease, and peripheral vascular disease were each associated with 10–30% increases in cost. Insulin treatment, angina, and MI were each associated with 60–90% increases in cost. Dialysis was associated with an 11-fold increase in cost. CONCLUSIONS—Insulin treatment and diabetes complications have a substantial impact on the direct medical costs of type 2 diabetes. The estimates presented in this model may be used to analyze the cost-effectiveness of interventions for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
Self-citationEffect of Improved Glycemic Control on Health Care Costs and Utilization
Wagner, E. H. (2001) · JAMA · doi:10.1001/jama.285.2.182 · Cited by 536
The CDC Diabetes Cost-effectiveness Group (2002) · JAMA · doi:10.1001/jama.287.19.2542 · Cited by 508
Health care expenditures for people with diabetes mellitus, 1992.
Rubin, R. J., Altman, W. M., & Mendelson, D. N. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.4.8157701 · Cited by 378
Excess Costs of Medical Care for Patients With Diabetes in a Managed Care Population
Selby, J. V., Ray, G. T., Zhang, D., & Colby, C. J. (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1396 · Cited by 344
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Copley-Merriman, C., Maier, W., Dong, F., Manninen, D., Zbrozek, A. S., Kotsanos, J., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.735 · Cited by 333
Self-citationModel of Complications of NIDDM: I. Model construction and assumptions
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Zbrozek, A. S., Dong, F., Manninen, D., Garfield, S. A., Copley-Merriman, C., Maier, W., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.725 · Cited by 258
Self-citationLifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.
Caro, J. J., Ward, A. J., & O’Brien, J. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.476 · Cited by 258
The Progressive Cost of Complications in Type 2 Diabetes Mellitus
Brown, J. B., Pedula, K. L., & Bakst, A. W. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1873 · Cited by 217
The Economic Costs of Non—Insulin-Dependent Diabetes Mellitus
Huse, D. M. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430190092037 · Cited by 190
Cited by
Epidemiology of Diabetes and Diabetes-Related Complications
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008) · Physical Therapy · doi:10.2522/ptj.20080020 · Cited by 1,773
Dixon, J. B., O’Brien, P. E., Playfair, J., Chapman, L., Schachter, L. M., Skinner, S., Proietto, J., Bailey, M., & Anderson, M. (2008) · JAMA · doi:10.1001/jama.299.3.316 · Cited by 1,434
Slow-wave sleep and the risk of type 2 diabetes in humans
Tasali, E., Leproult, R., Ehrmann, D. A., & Van Cauter, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706446105 · Cited by 921
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Metadata
- Authors
- Brandle, M., Zhou, H., Smith, B. R. K., Marriott, D., Burke, R., Tabaei, B. P., Brown, M. B., & Herman, W. H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-08-01
- Volume
- 26
- Issue
- 8
- Pages
- 2300-2304
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2121800587
- Cited by
- 269
- References
- 24
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Direct Medical Cost of Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/diacare.26.8.2300
- The paper
- Brandle, M., Zhou, H., Smith, B. R. K., Marriott, D., Burke, R., Tabaei, B. P., Brown, M. B., & Herman, W. H. (2003). The Direct Medical Cost of Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/diacare.26.8.2300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.